Incyte to Acquire Villaris Therapeutics for US$1.43 B
By Amit Kaushik
Pharma Deals Review: Vol 2022 Issue 10 (Table of Contents)
Published: 26 Oct-2022
DOI: 10.3833/pdr.v2022.i10.2739 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In order to boost its dermatology portfolio, Incyte has agreed to acquire Villaris Therapeutics, a biopharmaceutical firm focused on the development of novel antibody therapeutics...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS